A patent review of IDO1 inhibitors for cancer (2023–present): an update
1. 请及时下载文件确认是否正确, 系统将在 2025-06-05 11:41:23 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
H Qiu, Y Yin, Z Qin, D Li, P Wang
Expert Opinion on Therapeutic …, 2025
Taylor & Francis
ABSTRACT Introduction Indoleamine 2, 3-dioxygenase 1 (IDO1) is a promising target in cancer immunotherapy, yet its application faces significant challenges due to complex mechanisms of action. Recent advancements in IDO1 inhibitors aim to tackle these issues, potentially paving the way for successful therapeutic development. Areas covered This review highlights patent publications (2023–2024) related to IDO1 inhibitors with potential anti-cancer applications, sourced from Espacenet and Google Scholar. Expert opinion IDO1 …
